In a report released today, Timothy Ramey from Pivotal Research reiterated a Buy rating on USANA Health (USNA), with a price target of $95. The company’s shares closed yesterday at $84.15, close to its 52-week low of $83.
Ramey said:
“We are confident that the MLM model USANA operates is legal and ethical, around the world. Deceleration in China is clearly a worry, F/X, a stronger USD, has been a major negative for USANA.”
According to TipRanks.com, Ramey is a 4-star analyst with an average return of 8.5% and a 55.8% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for USANA Health with a $95 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $137.95 and a one-year low of $83. Currently, USANA Health has an average volume of 181.8K.
Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, and Sense-beautiful science.
